Figure 3 presents the prevalence of granulomas, symptoms mentioned during consultations with pulmonologists and neurologists, and pain as indicated in the SFNPQ for the skin, muscles and joints. The results show that symptoms in the skin, muscles and joints are often not caused by granulomas in those organ. Furthermore, patients report more symptoms via the SFNPQ than during consultations. The same trend is observed in patients with sarcoidosis, both with and without symptoms of SFN. Figure 3 Prevalence of granulomas, symptoms mentioned during consultations with physicians, and pain indicated in the small fiber neuropathy phenotyping questionnaire (SFNPQ) in healthy controls, patients with sarcoidosis without small fiber neuropathy (SFN), and sarcoidosis patients with SFN. Results were plotted for localization in the skin, muscles and joints. SFN, small fiber neuropathy; SFNPQ, small fiber neuropathy phenotyping questionnaire; HC, healthy controls; Prob., probable Figure 4 shows results for more detailed body areas based on three anatomical levels. The cutaneous and muscular levels showed the most areas with significantly more pain in patients with probable SFN. Cutaneous pain in the feet, hands, and back/abdomen were discriminatory for SFN. At the muscular level, symptoms in the thorax, arms, back/abdomen, and legs were distinctive for SFN. Joint symptoms were only more common in patients with sarcoidosis and probable SFN in the feet. Cutaneous symptoms in the feet and muscular symptoms in the legs showed the highest prevalence in sarcoidosis-associated SFN (67% vs 77% respectively). SFNPQ scores were significantly lower in healthy controls, except for pain in the head in the muscles and joints in patients with sarcoidosis and probable SFN, as well as for patients with sarcoidosis without SFN. Furthermore, patients with sarcoidosis without SFN showed no significant difference compared to healthy controls for pain in the back/abdomen in the skin and muscles. 4 74 4
RkJQdWJsaXNoZXIy MjY0ODMw